Influence of amlodipine and atenolol on lipopolysaccharide (LPS)-induced serum concentrations of TNF-α, IL-1β, IL-6 in spontaneously hypertensive rats (SHR)

Pharmacological Reports

Volumn 58, Issue 5, 2006, Pages 711-719

  Andrzejczak, Dariusz ^a   Górska, Dorota ^a   Czarnecka, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Amlodipine; Atenolol; Cytokines; LPS; SHR

Indexed keywords

AMLODIPINE; ATENOLOL; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; LIPOPOLYSACCHARIDE; METHYLCELLULOSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEEDING; HYPERTENSION; IMMUNOMODULATION; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

EID: 33751016810     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. ALLHAT Officers. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA, 2002, 288, 2981-2997.
2. Atkinson JB, Wudel JH, Hoff SJ, Stewart JR, Frist WH: Amlodipine reduces graft coronary artery disease in rat heterotopic cardiac allografts. J Heart Lung Transplant, 1993, 12, 1036-1043.
3. Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD: Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev, 2002, 16, 338-347.
4. Barton BE: IL-6: insights into novel biological activities. Clin Immunol Immunopathol, 1997, 85, 16-20.
5. Bautista LE: Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens, 2003, 17, 223-230.
6. Bautista LE, Vera LM, Arenas IA, Gamarra G: Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens, 2005, 19, 149-154.
7. Bernard C, Merval R, Esposito B, Tedgui A: Resistance to endotoxin shock in spontaneously hypertensive rats. Hypertension, 1998, 31, 1350-1356.
8. Bhagat K, Vallance P: Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation, 1997, 96, 3042-3047.
9. Brasier AR, Li J, Wimbish KA: Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension, 1996, 27, 1009-1017.
10. Chae CU, Lee RT, Rifai N, Ridker PM: Blood pressure and inflammation in apparently healthy men. Hypertension, 2001, 38, 399-403.
11. Chi DS, Fitzgerald SM, Pitts S, Cantor K, King E, Lee SA, Huang SK et al.: MAPK-dependent regulation of IL-1-and beta-adrenoreceptor-induced inflammatory cytokine production from mast cells: implications for the stress response. BMC Immunol, 2004, 5, 22-34.
12. Chou TC, Yang SP, Pei D: Amlodipine inhibits pro-inflammatory cytokines and free radical production and inducible nitric oxide synthase expression in lipopolysaccharide/interferon-gamma-stimulated cultured vascular smooth muscle cells. Jpn J Pharmacol, 2002, 89, 157-163.
13. Chou TC, Yen MH, Li CY, Ding YA: Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension, 1998, 31, 643-648.
14. Christensen JD, Hansen EW, Frederiksen C, Molris M, Moesby L: Adrenaline influences the release of interleukin-6 from murine pituicytes: role of beta2-adrenoceptors. Eur J Pharmacol, 1999, 378, 143-148.
15. Conrad KP, Miles TM, Benyo DF: Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol, 1998, 40, 102-111.
16. Dalekos GN, Elisaf M, Bairaktari E, Tsolas O, Siamopoulos KC: Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med, 1997, 129, 300-308.
17. Demirbas B, Güler S, Cakir B, Culha C, Aral Y: Plasma tumor necrosis factor-alpha levels and insulin resistance in nondiabetic hypertensive subjects. Horm Res, 2002, 58, 283-286.
18. Deng J, Muthu K, Gamelli R, Shankar R, Jones SB: Adrenergic modulation of splenic macrophage cytokine release in polymicrobial sepsis. Am J Physiol Cell Physiol, 2004, 287, C730-C736.
19. Dörffel Y, Latsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmester GR, Scholze J: Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension, 1999, 34, 113-117.
20. Dredge Y, Connor TJ, Kelly JP, Leonard BE: Differential effect of a single high dose of the tricyclic antidepressant imipramine on interleukin-1β and tumor necrosis factor-α secretion following an in vivo lipopolysaccharide challenge in rats. Int J Immunopharmacol, 1999, 21, 663-673.
21. Dzielak DJ: The immune system in hypertension. Hypertension, 1992, 19, 136-144.
22. Eickelberg O, Roth M, Mussmann R, Rudiger JJ, Tamm M, Perruchoud AP, Block LH: Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-kappaB in primary human vascular smooth muscle cells. Circulation, 1999, 99, 2276-2282.
23. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES: The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev, 2000, 52, 595-638.
24. Ersoy C, Imamoglu S, Budak F, Tuncel E, Ertürk E, Oral B: Effect of amlodipine on insulin resistance and tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients. Indian J Med Res, 2004, 120, 481-488.
25. Feingold KR, Staprans I, Memon RA, Moser AH, Shigenaga K Doerrler W, Dinarello CA et al.: Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res, 1992, 33, 1765-1776.
26. Fiers W: Tumor necrosis factor. Characterization of the molecular, cellular and in vivo level. FEBS Lett, 1991, 285, 199-212.
27. Fukuzawa M, Satoh J, Ohta S, Takahashi K, Miyaguchi S, Qiang X, Sakata Y et al.: Modulation of tumor necrosis factor-α production with anti-hypertensive drugs. Immunopharmacology, 2000, 48, 65-74.
28. Görska D, Andrzejczak D: Influence of mianserin on the activity of some hypotensive drugs in spontaneously hypertensive rats. Pol J Pharmacol, 2003, 55, 409-417.
29. Grimm RH Jr, Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, Lewis L et al.: Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA, 1996, 275, 1549-1556.
30. Iritani N, Fukuda E, Nara Y, Yamori Y: Lipid metabolism in spontaneously hypertensive rats (SHR). Atherosclerosis, 1977, 28, 217-222.
31. Kawasaki M, Yagasaki K, Miura Y, Funabiki R: Comparison of the changes in lipid metabolism between hepatoma-bearing and lipopolysaccharide-treated rats. Biosci Biotechnol Biochem, 2004, 68, 72-78.
32. Kumai T, Oonuma S, Kitaoka Y, Tadokoro M, Kobayashi S: Biochemical and morphological characterization of spontaneously hypertensive hyperlipidaemic rats. Clin Exp Pharmacol Physiol, 2003, 30, 537-544.
33. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med, 1990, 323, 236-241.
34. Liu Y, Liu T, McCarron RM, Spatz M, Feuerstein G, Hallenbeck JM, Sirén AL: Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol Heart Circ Physiol, 1996, 270, H2125-H2131.
35. Mason RP, Marche P, Hintze TH: Novel vascular biology of third-generation 1-type calcium channel antagonists. Ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol, 2003, 23, 2155-2163.
36. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol, 1999, 31, 275-281.
37. Mastronardi CA, Yu WH, McCann S: Lipopolysaccharide-induced tumor necrosis factor-α release is controlled by the central nervous system. Neuroimmunomodulation, 2001, 9, 148-156.
38. Mohler ER 3rd, Sorensen LC, Ghali JK, Schocken DD, Willis PW, Bowers JA, Cropp AB et al.: Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol, 1997, 30, 35-41.
39. Murray DR, Prabhu SD, Chandrasekar B: Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation, 2000, 101, 2338-2341.
40. Nakamura A, Johns EJ, Abe T, Kohsaka T: Role of beta-adrenoceptor on renal interleukin-6 and tumor necrosis factor in spontaneously hypertensive rats. Life Sci, 1998, 62, 2407-2416.
41. Nakamura A, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T: Effect of beta(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells. Cytokine, 1999, 11, 759-765.
42. Nayler WG: End-organ involvement and calcium antagonist therapy: animal studies. J Cardiovasc Pharmacol, 1994, 24, S12-S17.
43. Okamoto K, Aoki K: Development of a strain of spontaneously hypertensive rats. Jpn Circ J, 1963, 27, 282-293.
44. Opal SM, DePalo VA: Anti-Inflammatory cytokines. Chest, 2000, 117, 1162-1172.
45. 2+ handling in spontaneously hypertensive rats. Hypertens Res, 2003, 26, 901-906.
46. Peeters ACTM, Netea MG, Janssen MCH, Kullberg BJ, Van der Meer JWM, Thien T: Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest, 2001, 31, 31-36.
47. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL: β-Adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation, 2000, 101, 2103-2109.
48. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med, 1999, 340, 115-126.
49. Rödler S, Roth M, Nauck M, Tamm M, Block LH: Ca(2+)-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells. J Mol Cell Cardiol, 1995, 27, 2295-2302.
50. Salomon P, Halawa B, Karolko B: Influence of amlodipine on serum level of some cytokines in patients with congestive heart failure. (Polish) Pol Arch Med Wewn, 2003, 109, 149-155.
51. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Fontana L, Campo S, Campo GM et al.: Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-α levels in uncomplicated hypertensive patients. Angiology, 2004, 55, 195-203.
52. Sattar N, McCarey DW, Capell H, McInnes IB: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation, 2003, 108, 2957-2963.
53. Sheu WHH, Lee WJ, Chang RL, Chen YT: Plasma tumor necrosis factor α levels and insulin sensitivity in hypertensive subjects. Clin Exp Hypertens, 2000, 22, 595-606.
54. Sirén AL, Heldman E, Doron D, Lysko PG, Yue TL, Liu Y, Feuerstein G et al.: Release of proinflammatory and prothrombotic mediators in the brain and peripheral circulation in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Stroke, 1992, 23, 1643-1650.
55. Srinivasan PS, Hakim ZS, Santani DD, Goyal RK: Effects of chronic treatment with amlodipine in streptozotocin-diabetic and spontaneously hypertensive rats. Pharmacol Res, 1997, 35, 423-428.
56. Takeichi N, Suzuki K, Kobayashi H: Characterization of immunological depression in spontaneously hypertensive rats. Eur J Immunol, 1981, 11, 483-487.
57. Takeichi N, Suzuki K, Okayasu T, Kobayashi H: Immunological depression in spontaneously hypertensive rats. Clin Exp Immunol, 1980, 40, 120-126.
58. Torre-Amione G, Vooletich MT, Farmer JA: Role of tumour necrosis factor-α in the progression of heart failure. Drugs, 2000, 59, 745-751.
59. Turgan N, Habif S, Kabaroglu CG, Mutaf II, Özmen D, Bayindir O, Uysal A: Effects of the calcium channel blocker amlodipine on serum and aortic cholesterol, lipid peroxidation, antioxidant status and aortic histology in cholesterol-fed rabbits. J Biomed Sci, 2003, 10, 65-72.
60. Van Snick J: Interleukin-6, an overview. Annu Rev Immunol, 1990, 8, 253-278.
61. Vila E, Salaices M: Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol, 2005, 288, 1016-1021.
62. Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S, Kobayashi J et al.: Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology, 1997, 54, 144-152.
63. Yoshizumi M, Perella MA, Burnett JC Jr, Lee ME: Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res, 1993, 73, 205-209.
64. Yuan YV, Kitts DD, Godin DV: Heart and red blood cell antioxidant status and plasma lipid levels in the spontaneously hypertensive and normotensive Wistar-Kyoto rat. Can J Physiol Pharmacol, 1996, 74, 290-297.
65. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, and coronary heart disease: is interleukin-6 the link? Atherosclerosis, 2000, 148, 209-214.